Are Emerging Fixed-Dose Combinations Poised to Fill the Unmet Need for Drugs with Greater Efficacy? Type 2 diabetes is a major public health concern, affecting more than 30 million people in the…
With the High Efficacy Bar That TNF-Alpha Inhibitors Set, What Are the Remaining Areas of Opportunities for Emerging Therapies to Fill? Nine biologics are approved to treat rheumatoid arthritis (…
With the High Efficacy Bar That TNF-Alpha Inhibitors Set, What Are the Remaining Areas of Opportunities for Emerging Therapies to Fill? Nine biologics are approved to treat rheumatoid arthritis (…
Methicillin-resistant Staphylococcus aureus (MRSA) is a clinically-important Gram-positive pathogen in both the hospital and outpatient settings. Over the past decade, the MRSA hospital market has…
This quarterly report provides a detailed analysis of emerging and current therapies in nephrology based on responses from surveyed U.S. nephrologists. Emphasis is on anemia management (ESAs and IV…
The launches of sipuleucel-T (Dendreon’s Provenge) and ipilimumab (Bristol-Myers Squibb’s Yervoy) in 2010 and 2011, respectively, represented the first notable immunotherapy approvals in…
The market opportunity for hepatitis C virus (HCV) is marked by a large prevalent population and high unmet medical need due to the suboptimal tolerability and efficacy of early, interferon-based…
Major depressive disorder (MDD) continues to be a highly prevalent psychiatric disorder. Over 5 million drug-treated MDD patients in the United States fail to respond adequately to treatment with…
Huntington’s disease (HD) is a fatal neurodegenerative disease characterized by uncoordinated and uncontrollable movements, cognitive deterioration, as well as behavioral and/or psychological…
Oncologists Are Eager for Therapies Extending Overall Survival Ovarian cancer (CaO) ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female…
In Europe, multiple myeloma (MM) treatment is centered on the use of three major agents—Janssen’s Velcade (bortezomib), Celgene’s Revlimid (lenalidomide), and Celgene’s Thalidomide (…
Oncologists Are Eager for Therapies Extending Overall Survival Ovarian cancer (CaO) ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female…
Last Updated 22 May 2014 Although colectomy is curative for the potentially fatal immune disease ulcerative colitis (UC), this procedure is life altering, and therefore unmet need remains for…
With Few Good Treatment Choices, Which Emerging Therapies Hold the Greatest Potential for Managing AML and What Types of Therapies Will Receive Reimbursement? Despite the introduction and use of…
As Abiraterone and Enzalutamide Gain Traction in the Market, What Key Attributes Do Oncologists and Payers Say Will Differentiate Emerging Therapies? The first-line (chemotherapy-naive) metastatic…